Published in EMBO Mol Med on March 01, 2010
Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists. Nature (2015) 2.45
An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. Genes Dev (2011) 2.38
The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood (2011) 2.23
Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis. Cell (2011) 2.11
BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint. Nat Med (2013) 1.79
BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia. Nat Chem Biol (2012) 1.77
Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice. Blood (2012) 1.67
Ebf1 or Pax5 haploinsufficiency synergizes with STAT5 activation to initiate acute lymphoblastic leukemia. J Exp Med (2011) 1.49
Critical requirement for Stat5 in a mouse model of polycythemia vera. Blood (2011) 1.48
PI3Kδ is essential for tumor clearance mediated by cytotoxic T lymphocytes. PLoS One (2012) 1.16
Transcription factor Ebf1 regulates differentiation stage-specific signaling, proliferation, and survival of B cells. Genes Dev (2012) 1.13
STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia. Oncotarget (2012) 1.12
Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies. J Cell Mol Med (2012) 1.10
JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo. Blood (2014) 1.08
Genome-wide analyses reveal the extent of opportunistic STAT5 binding that does not yield transcriptional activation of neighboring genes. Nucleic Acids Res (2012) 1.04
The role of STAT5 in lymphocyte development and transformation. Curr Opin Immunol (2012) 0.98
Mechanistic rationale for targeting the unfolded protein response in pre-B acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2014) 0.95
Intracellular retention of ABL kinase inhibitors determines commitment to apoptosis in CML cells. PLoS One (2012) 0.95
The role of the Janus-faced transcription factor PAX5-JAK2 in acute lymphoblastic leukemia. Blood (2014) 0.94
PAK-dependent STAT5 serine phosphorylation is required for BCR-ABL-induced leukemogenesis. Leukemia (2013) 0.92
Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine-kinase inhibitor combinations and beyond. Hematology Am Soc Hematol Educ Program (2013) 0.91
Structure, regulation, signaling, and targeting of abl kinases in cancer. Genes Cancer (2012) 0.90
Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia. Leukemia (2014) 0.90
Role of STAT3 in Transformation and Drug Resistance in CML. Front Oncol (2012) 0.89
Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemia. Sci Transl Med (2015) 0.89
Mouse models as tools to understand and study BCR-ABL1 diseases. Am J Blood Res (2011) 0.88
Transforming and tumorigenic activity of JAK2 by fusion to BCR: molecular mechanisms of action of a novel BCR-JAK2 tyrosine-kinase. PLoS One (2012) 0.88
The PPARα agonist fenofibrate suppresses B-cell lymphoma in mice by modulating lipid metabolism. Biochim Biophys Acta (2013) 0.87
Diverging fates of cells of origin in acute and chronic leukaemia. EMBO Mol Med (2012) 0.86
The Philadelphia chromosome in leukemogenesis. Chin J Cancer (2016) 0.86
STAT5 is crucial to maintain leukemic stem cells in acute myelogenous leukemias induced by MOZ-TIF2. Cancer Res (2012) 0.85
Signal transduction in the chronic leukemias: implications for targeted therapies. Curr Hematol Malig Rep (2013) 0.84
Deletion of the RNA-editing enzyme ADAR1 causes regression of established chronic myelogenous leukemia in mice. Int J Cancer (2012) 0.84
A requirement for SOCS-1 and SOCS-3 phosphorylation in Bcr-Abl-induced tumorigenesis. Neoplasia (2012) 0.83
BCR-ABL affects STAT5A and STAT5B differentially. PLoS One (2014) 0.83
Regulation of the interferon regulatory factor-8 (IRF-8) tumor suppressor gene by the signal transducer and activator of transcription 5 (STAT5) transcription factor in chronic myeloid leukemia. J Biol Chem (2014) 0.82
Kinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitors. Stem Cells Transl Med (2014) 0.82
Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy. Haematologica (2014) 0.82
STAT5-mediated self-renewal of normal hematopoietic and leukemic stem cells. JAKSTAT (2012) 0.81
Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia. J Clin Invest (2016) 0.81
Inhibition of STAT5: a therapeutic option in BCR-ABL1-driven leukemia. Oncotarget (2014) 0.80
Stat5-deficient hematopoiesis is permissive for Myc-induced B-cell leukemogenesis. Oncotarget (2015) 0.80
STAT5 acetylation: Mechanisms and consequences for immunological control and leukemogenesis. JAKSTAT (2013) 0.80
Acetylation and sumoylation control STAT5 activation antagonistically. JAKSTAT (2012) 0.80
Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway. Cancer Biol Ther (2012) 0.80
Cutting edge: cell-autonomous control of IL-7 response revealed in a novel stage of precursor B cells. J Immunol (2013) 0.80
STAT5-regulated microRNA-193b controls haematopoietic stem and progenitor cell expansion by modulating cytokine receptor signalling. Nat Commun (2015) 0.80
IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms. Oncotarget (2016) 0.80
Regulation of hTERT by BCR-ABL at multiple levels in K562 cells. BMC Cancer (2011) 0.80
Acceleration of Bcr-Abl+ leukemia induced by deletion of JAK2. Leukemia (2014) 0.79
Stat5 Exerts Distinct, Vital Functions in the Cytoplasm and Nucleus of Bcr-Abl+ K562 and Jak2(V617F)+ HEL Leukemia Cells. Cancers (Basel) (2015) 0.79
Adding a new facet to STAT5 in CML: multitasking for leukemic cells. Cell Cycle (2013) 0.79
Novel mechanism of tumor suppression by polarity gene discs large 1 (DLG1) revealed in a murine model of pediatric B-ALL. Cancer Immunol Res (2013) 0.79
The inhibition of stat5 by a Peptide aptamer ligand specific for the DNA binding domain prevents target gene transactivation and the growth of breast and prostate tumor cells. Pharmaceuticals (Basel) (2013) 0.79
Conditional inactivation of Blimp1 in adult mice promotes increased bone mass. J Biol Chem (2012) 0.79
LCK over-expression drives STAT5 oncogenic signaling in PAX5 translocated BCP-ALL patients. Oncotarget (2015) 0.78
C/EBPβ promotes BCR-ABL-mediated myeloid expansion and leukemic stem cell exhaustion. Leukemia (2012) 0.78
Context-Specific Growth Hormone Signaling through the Transcription Factor STAT5: Implications for the Etiology of Hepatosteatosis and Hepatocellular Carcinoma. Genes Cancer (2011) 0.78
Depletion of STAT5 blocks TEL-SYK-induced APMF-type leukemia with myelofibrosis and myelodysplasia in mice. Blood Cancer J (2014) 0.77
A screening-based approach to circumvent tumor microenvironment-driven intrinsic resistance to BCR-ABL+ inhibitors in Ph+ acute lymphoblastic leukemia. J Biomol Screen (2013) 0.77
Structure-Based Screen Identifies a Potent Small Molecule Inhibitor of Stat5a/b with Therapeutic Potential for Prostate Cancer and Chronic Myeloid Leukemia. Mol Cancer Ther (2015) 0.77
LNK/SH2B3 regulates IL-7 receptor signaling in normal and malignant B-progenitors. J Clin Invest (2016) 0.77
Loss of STAT3 in Lymphoma Relaxes NK Cell-Mediated Tumor Surveillance. Cancers (Basel) (2014) 0.77
FRA2 is a STAT5 target gene regulated by IL-2 in human CD4 T cells. PLoS One (2014) 0.77
Targeting endogenous proteins for degradation through the affinity-directed protein missile system. Open Biol (2017) 0.76
Genetically engineered mouse models of human B-cell precursor leukemias. Cell Cycle (2014) 0.76
Co-existence of IL7R high and SH2B3 low expression distinguishes a novel high-risk acute lymphoblastic leukemia with Ikaros dysfunction. Oncotarget (2016) 0.76
BM microenvironmental protection of CML cells from imatinib through Stat5/NF-κB signaling and reversal by Wogonin. Oncotarget (2016) 0.76
Oncogenic STAT5 signaling promotes oxidative stress in chronic myeloid leukemia cells by repressing antioxidant defenses. Oncotarget (2017) 0.76
STAT5 activation in B-cell acute lymphoblastic leukemia: damned if you do, damned if you don't. Cancer Cell Microenviron (2016) 0.76
Src family kinases interfere with dimerization of STAT5A through a phosphotyrosine-SH2 domain interaction. Cell Commun Signal (2015) 0.76
New Developments in Chronic Myeloid Leukemia: Implications for Therapy. Iran J Cancer Prev (2016) 0.75
Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML. Clin Cancer Res (2015) 0.75
MYC selects against reduced BCL2A1/A1 protein expression during B cell lymphomagenesis. Oncogene (2016) 0.75
Overexpression of hepatoma-derived growth factor in melanocytes does not lead to oncogenic transformation. BMC Cancer (2011) 0.75
It is a differentiation game: STAT5 in a new role. Cell Death Differ (2017) 0.75
Overview of the Use of Murine Models in Leukemia and Lymphoma Research. Front Oncol (2017) 0.75
Dual-inhibitors of STAT5 and STAT3: studies from molecular docking and molecular dynamics simulations. J Mol Model (2014) 0.75
Gadd45a deficiency accelerates BCR-ABL driven chronic myelogenous leukemia. Oncotarget (2017) 0.75
Activation of PPARγ by endogenous prostaglandin J2 mediates the antileukemic effect of selenium in murine leukemia. Blood (2017) 0.75
How Intrinsic Molecular Dynamics Control Intramolecular Communication in Signal Transducers and Activators of Transcription Factor STAT5. PLoS One (2015) 0.75
Intramolecular hydrophobic interactions are critical mediators of STAT5 dimerization. Sci Rep (2016) 0.75
Antagonism of B cell enhancer networks by STAT5 drives leukemia and poor patient survival. Nat Immunol (2017) 0.75
Differential signaling networks of Bcr-Abl p210 and p190 kinases in leukemia cells defined by functional proteomics. Leukemia (2017) 0.75
SOCS1 function in BCR-ABL mediated myeloproliferative disease is dependent on the cytokine environment. PLoS One (2017) 0.75
The hallmarks of cancer. Cell (2000) 113.05
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med (2001) 24.51
An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature (2005) 22.40
Cancer. Addiction to oncogenes--the Achilles heal of cancer. Science (2002) 14.20
The STATs of cancer--new molecular targets come of age. Nat Rev Cancer (2004) 13.07
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell (2002) 13.03
Restoration of p53 function leads to tumour regression in vivo. Nature (2007) 12.62
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med (2001) 11.88
Principles of cancer therapy: oncogene and non-oncogene addiction. Cell (2009) 10.96
Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature (2007) 9.12
Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci U S A (1997) 7.08
Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood (1998) 6.81
Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res (2002) 5.84
Global analysis of proliferation and cell cycle gene expression in the regulation of hematopoietic stem and progenitor cell fates. J Exp Med (2005) 5.68
Principles of tumor suppression. Cell (2004) 5.52
The molecular biology of chronic myeloid leukemia. Blood (2000) 5.22
Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature (2009) 4.99
Stat proteins and oncogenesis. J Clin Invest (2002) 4.79
Inactivation of Stat5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation. Mol Cell Biol (2004) 4.45
JunB deficiency leads to a myeloproliferative disorder arising from hematopoietic stem cells. Cell (2004) 4.28
Sox17 dependence distinguishes the transcriptional regulation of fetal from adult hematopoietic stem cells. Cell (2007) 4.18
Cancer stem cells: lessons from leukemia. Trends Cell Biol (2005) 3.90
Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science (2009) 3.89
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer (2007) 3.89
Stat5a/b are essential for normal lymphoid development and differentiation. Proc Natl Acad Sci U S A (2006) 3.66
Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell (2008) 3.01
Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell (2008) 2.80
JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia (2004) 2.76
The journey of developing hematopoietic stem cells. Development (2006) 2.71
Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat Med (2006) 2.69
Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med (1996) 2.68
Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood (2004) 2.57
P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem (1996) 2.47
Distinct effects of STAT5 activation on CD4+ and CD8+ T cell homeostasis: development of CD4+CD25+ regulatory T cells versus CD8+ memory T cells. J Immunol (2003) 2.47
Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2. Mol Cell (2000) 2.41
Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov (2007) 2.40
Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation. Blood (2006) 2.38
Leukemia stem cells in a genetically defined murine model of blast-crisis CML. Blood (2007) 2.34
Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol Cell Biol (2006) 2.28
Stat5 tetramer formation is associated with leukemogenesis. Cancer Cell (2005) 2.26
Signal transducer and activator of transcription proteins in leukemias. Blood (2002) 2.23
Knockdown of STAT3 expression by RNA interference inhibits the induction of breast tumors in immunocompetent mice. Cancer Res (2005) 2.20
Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene (1996) 2.17
Murine hematopoietic stem cells change their surface phenotype during ex vivo expansion. Blood (2005) 2.05
Antiapoptotic BCL-2 is required for maintenance of a model leukemia. Cancer Cell (2004) 1.92
STAT signaling in the pathogenesis and treatment of leukemias. Oncogene (2000) 1.81
Stat5a/b contribute to interleukin 7-induced B-cell precursor expansion, but abl- and bcr/abl-induced transformation are independent of stat5. Blood (2000) 1.74
Selective activation of STAT5 unveils its role in stem cell self-renewal in normal and leukemic hematopoiesis. J Exp Med (2005) 1.72
Loss of p53 impedes the antileukemic response to BCR-ABL inhibition. Proc Natl Acad Sci U S A (2006) 1.71
Antiapoptotic activity of Stat5 required during terminal stages of myeloid differentiation. Genes Dev (2000) 1.61
Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. J Immunol (1997) 1.59
Conditional deletion of STAT5 in adult mouse hematopoietic stem cells causes loss of quiescence and permits efficient nonablative stem cell replacement. Blood (2009) 1.58
Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML). Blood (2005) 1.53
Right on target: eradicating leukemic stem cells. Trends Mol Med (2007) 1.49
STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. Blood (2000) 1.44
STAT5 activation by BCR-Abl contributes to transformation of K562 leukemia cells. Blood (1999) 1.29
Stat5 activation enables erythropoiesis in the absence of EpoR and Jak2. Blood (2008) 1.20
STAT5 requires the N-domain to maintain hematopoietic stem cell repopulating function and appropriate lymphoid-myeloid lineage output. Exp Hematol (2007) 1.19
The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis. Mayo Clin Proc (2005) 1.17
Constitutive activation of STAT3 and STAT5 is induced by leukemic fusion proteins with protein tyrosine kinase activity and is sufficient for transformation of hematopoietic precursor cells. Exp Hematol (2002) 1.14
JAK2 mutations in myeloproliferative disorders. N Engl J Med (2005) 1.09
The different functions of Stat5 and chromatin alteration through Stat5 proteins. Front Biosci (2008) 1.05
Fusion of the ets transcription factor TEL to Jak2 results in constitutive Jak-Stat signaling. Blood (1999) 1.04
Models of chronic myeloid leukemia. Curr Oncol Rep (2001) 1.00
The dark and the bright side of Stat3: proto-oncogene and tumor-suppressor. Front Biosci (Landmark Ed) (2009) 0.96
Constitutive and specific activation of STAT3 by BCR-ABL in embryonic stem cells. Oncogene (2003) 0.93
BCL2 gene polymorphism could predict the treatment outcomes in acute myeloid leukemia patients. Leuk Res (2009) 0.92
Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity (2007) 12.12
Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol (2005) 11.46
Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat Immunol (2006) 7.89
A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell (2007) 5.85
DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene (2005) 5.74
Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells. Proc Natl Acad Sci U S A (2006) 5.69
Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. J Cell Biol (2002) 5.07
NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest (2004) 5.06
Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat Rev Mol Cell Biol (2003) 4.53
Nonredundant roles for Stat5a/b in directly regulating Foxp3. Blood (2007) 4.50
Inactivation of Stat5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation. Mol Cell Biol (2004) 4.45
Stat5a/b are essential for normal lymphoid development and differentiation. Proc Natl Acad Sci U S A (2006) 3.66
p38alpha suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway. Nat Genet (2007) 3.19
An adjunct mammary epithelial cell population in parous females: its role in functional adaptation and tissue renewal. Development (2002) 3.16
Genetic evidence supporting selection of the Valpha14i NKT cell lineage from double-positive thymocyte precursors. Immunity (2005) 2.72
Autocrine PDGFR signaling promotes mammary cancer metastasis. J Clin Invest (2006) 2.68
Expression profiling of epithelial plasticity in tumor progression. Oncogene (2003) 2.67
Activation of PPAR gamma and delta by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease. Gastroenterology (2004) 2.65
Structural coupling of SH2-kinase domains links Fes and Abl substrate recognition and kinase activation. Cell (2008) 2.46
Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis. Cancer Cell (2011) 2.46
Molecular aspects of epithelial cell plasticity: implications for local tumor invasion and metastasis. Mutat Res (2004) 2.45
Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of interstitial matrix deposition, and heart protection from ischemic injury. Circ Res (2004) 2.45
Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland. Development (2002) 2.42
Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation. Blood (2006) 2.38
Impairment of hepatic growth hormone and glucocorticoid receptor signaling causes steatosis and hepatocellular carcinoma in mice. Hepatology (2011) 2.33
RIP-Cre revisited, evidence for impairments of pancreatic beta-cell function. J Biol Chem (2005) 2.32
Hepatocytes convert to a fibroblastoid phenotype through the cooperation of TGF-beta1 and Ha-Ras: steps towards invasiveness. J Cell Sci (2002) 2.32
ILEI: a cytokine essential for EMT, tumor formation, and late events in metastasis in epithelial cells. Cancer Cell (2006) 2.30
Stat3 controls lysosomal-mediated cell death in vivo. Nat Cell Biol (2011) 2.28
STAT3 contributes to the mitogenic response of hepatocytes during liver regeneration. J Biol Chem (2002) 2.28
Stat5 tetramer formation is associated with leukemogenesis. Cancer Cell (2005) 2.26
Stat3 regulates microtubules by antagonizing the depolymerization activity of stathmin. J Cell Biol (2006) 2.21
Signaling by intrathymic cytokines, not T cell antigen receptors, specifies CD8 lineage choice and promotes the differentiation of cytotoxic-lineage T cells. Nat Immunol (2010) 2.19
Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia (2005) 2.18
Hepatocyte-specific disruption of Bcl-xL leads to continuous hepatocyte apoptosis and liver fibrotic responses. Gastroenterology (2004) 2.18
Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis. Cell (2011) 2.11
The erythroid phenotype of EKLF-null mice: defects in hemoglobin metabolism and membrane stability. Mol Cell Biol (2005) 2.11
Postnatal body growth is dependent on the transcription factors signal transducers and activators of transcription 5a/b in muscle: a role for autocrine/paracrine insulin-like growth factor I. Endocrinology (2006) 2.10
Evidence for a size-sensing mechanism in animal cells. Nat Cell Biol (2004) 2.09
High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood (2011) 2.08
Leukemic challenge unmasks a requirement for PI3Kdelta in NK cell-mediated tumor surveillance. Blood (2008) 2.04
Hematopoietic-specific Stat5-null mice display microcytic hypochromic anemia associated with reduced transferrin receptor gene expression. Blood (2008) 2.01
STAT1 acts as a tumor promoter for leukemia development. Cancer Cell (2006) 2.00
Interleukin 7 signaling in dendritic cells regulates the homeostatic proliferation and niche size of CD4+ T cells. Nat Immunol (2009) 1.98
Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res (2002) 1.96
Reduced lymphomyeloid repopulating activity from adult bone marrow and fetal liver of mice lacking expression of STAT5. Blood (2002) 1.96
Mutational switch of an IL-6 response to an interferon-gamma-like response. Proc Natl Acad Sci U S A (2002) 1.96
Lipoxygenase mediates invasion of intrametastatic lymphatic vessels and propagates lymph node metastasis of human mammary carcinoma xenografts in mouse. J Clin Invest (2011) 1.88
Membrane lipidome of an epithelial cell line. Proc Natl Acad Sci U S A (2011) 1.87
Helper T cell IL-2 production is limited by negative feedback and STAT-dependent cytokine signals. J Exp Med (2007) 1.83
TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia. Cancer Discov (2013) 1.81
The cell death regulator GRIM-19 is an inhibitor of signal transducer and activator of transcription 3. Proc Natl Acad Sci U S A (2003) 1.80
The canonical Notch/RBP-J signaling pathway controls the balance of cell lineages in mammary epithelium during pregnancy. Dev Biol (2006) 1.80
beta-Catenin and TGFbeta signalling cooperate to maintain a mesenchymal phenotype after FosER-induced epithelial to mesenchymal transition. Oncogene (2004) 1.79
Impaired differentiation and lactational failure of Erbb4-deficient mammary glands identify ERBB4 as an obligate mediator of STAT5. Development (2003) 1.79
Tumor suppression by phospholipase C-beta3 via SHP-1-mediated dephosphorylation of Stat5. Cancer Cell (2009) 1.78
Epidermal growth factor receptor signaling synergizes with Hedgehog/GLI in oncogenic transformation via activation of the MEK/ERK/JUN pathway. Cancer Res (2009) 1.78
Loss of signal transducer and activator of transcription 5 leads to hepatosteatosis and impaired liver regeneration. Hepatology (2007) 1.77
GFP expression in the mammary gland for imaging of mammary tumor cells in transgenic mice. Cancer Res (2002) 1.77
BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia. Nat Chem Biol (2012) 1.77
Tumor cell invasiveness correlates with changes in integrin expression and localization. Oncogene (2005) 1.73
Different steroids co-regulate long-term expansion versus terminal differentiation in primary human erythroid progenitors. Blood (2004) 1.70
A STAT3-mediated metabolic switch is involved in tumour transformation and STAT3 addiction. Aging (Albany NY) (2010) 1.70
Development of mammary luminal progenitor cells is controlled by the transcription factor STAT5A. Genes Dev (2009) 1.69
Early onset of neoplasia in the prostate and skin of mice with tissue-specific deletion of Pten. Proc Natl Acad Sci U S A (2004) 1.67
NF-kappaB promotes epithelial-mesenchymal transition, migration and invasion of pancreatic carcinoma cells. Cancer Lett (2010) 1.67
Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice. Blood (2012) 1.67
PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. Nat Med (2012) 1.67
HOXB4 enforces equivalent fates of ES-cell-derived and adult hematopoietic cells. Proc Natl Acad Sci U S A (2005) 1.65
CD14 is a coreceptor of Toll-like receptors 7 and 9. J Exp Med (2010) 1.64
Stat3 is a negative regulator of intestinal tumor progression in Apc(Min) mice. Gastroenterology (2009) 1.64
Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response. Eur J Immunol (2013) 1.63
Directed differentiation and mass cultivation of pure erythroid progenitors from mouse embryonic stem cells. Blood (2004) 1.62
The STAT3 isoforms alpha and beta have unique and specific functions. Nat Immunol (2004) 1.62
Ups and downs: the STAT1:STAT3 seesaw of Interferon and gp130 receptor signalling. Semin Cell Dev Biol (2008) 1.62
Alpha interferon induces long-lasting refractoriness of JAK-STAT signaling in the mouse liver through induction of USP18/UBP43. Mol Cell Biol (2009) 1.61
Critical role for Stat3 in T-dependent terminal differentiation of IgG B cells. Blood (2005) 1.60